Targets › GSH
4 programs from 3 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: the race on GSH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Emmanuelle Waubant, MD PhD | N-acetyl cysteine Glutathione (GSH) precursor with antioxidant properties | GSH | Phase 2 | Multiple Sclerosis | Feb 2027 |
| Weill Medical College of Cornell University | NAC 3600mg/day Precursor for glutathione (GSH) synthesis; antioxidant and mucolytic agent that replenishe | GSH | Phase 2 | Chronic Fatigue Syndrome | Apr 2027 |
| Weill Medical College of Cornell University | NAC 900mg/day Precursor for glutathione (GSH) synthesis; antioxidant and mucolytic agent that replenishe | GSH | Phase 2 | Chronic Fatigue Syndrome | Apr 2027 |
| Michio Hirano, MD | N-Acetylcysteine Glutathione precursor and antioxidant; increases brain glutathione levels | GSH | Phase 1 | Mitochondrial Disease | – |
Chronic Fatigue Syndrome (2) Multiple Sclerosis (1) Mitochondrial Disease (1)
small molecule (4)
Weill Medical College of Cornell University (2) Emmanuelle Waubant, MD PhD (1) Michio Hirano, MD (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.